Literature DB >> 9133505

Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy.

W V Dörffel1, S B Felix, G Wallukat, S Brehme, K Bestvater, T Hofmann, F X Kleber, G Baumann, P Reinke.   

Abstract

BACKGROUND: Previous studies have shown that the sera of many patients with dilated cardiomyopathy (DCM) are positive for several antibodies directed against cardiac antigens. Anti-beta1-adrenergic receptor antibodies occur in 70% to 90% of DCM patients. These antibodies are extractable by immunoadsorption (IA). In an investigation of the functional significance of antibodies for hemodynamics, IA was performed throughout 5 consecutive days on nine patients with severe DCM who were on stable drug therapy. METHODS AND
RESULTS: Immunoglobulins were eliminated in nine patients with severe DCM (mean age, 43.5 years; range, 25 to 58 years; left ventricular ejection fraction, <25%). IA was performed over 5 consecutive days with an immunoadsorber for immunoglobulin. All patients were on stable medication, including ACE inhibitors, digitalis, and diuretics. All patients received beta-blockers. During therapy, hemodynamic parameters (mean+/-SD) were monitored with a Swan-Ganz thermodilution catheter. IA elicited a decrease of anti-beta1-adrenergic receptor antibodies from 6.4+/-1.3 to 1.0+/-0.5 relative units. During IA, cardiac output increased from 3.7+/-0.8 to 5.5+/-1.8 L/min, P<.01. Mean arterial pressure decreased from 76.0+/-9.9 to 65.0+/-11.2 mm Hg, P<.05; mean pulmonary arterial pressure, from 27.6+/-7.7 to 22.0+/-6.5 mm Hg, P<.05; left ventricular filling pressure, from 16.8+/-7.4 to 12.8+/-4.7 mm Hg, P<.05; and systemic vascular resistance, from 1465+/-332 to 949+/-351 dyne x s x cm(-5), P<.01.
CONCLUSIONS: In addition to conventional medical treatment, IA may be an additional therapeutic possibility for acute hemodynamic stabilization of patients with severe DCM.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9133505     DOI: 10.1161/01.cir.95.8.1994

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  24 in total

1.  Anti beta1-adrenoceptor autoantibodies analyzed in spontaneously beating neonatal rat heart myocyte cultures-comparison of methods.

Authors:  G Wallukat; E Nissen
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-03       Impact factor: 2.416

Review 2.  Role of autoantibodies in the physiopathology of Chagas' disease.

Authors:  Emiliano Horacio Medei; José Hamilton Matheus Nascimento; Roberto Coury Pedrosa; Antônio Carlos Campos de Carvalho
Journal:  Arq Bras Cardiol       Date:  2008-10       Impact factor: 2.000

3.  IgG subclass reactivity to human cardiac myosin in cardiomyopathy patients is indicative of a Th1-like autoimmune disease.

Authors:  P Skyllouriotis; M Skyllouriotis-Lazarou; S Natter; R Steiner; S Spitzauer; S Kapiotis; P Valent; A M Hirschl; S E Guber; G Laufer; G Wollenek; E Wolner; M Wimmer; R Valenta
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

Review 4.  Autoantibodies and cardiovascular dysfunction: cause or consequence?

Authors:  Yuji Nagatomo; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2014-12

Review 5.  [Therapy of dilated cardiomyopathies with and without inflammation].

Authors:  G Hufnagel; S Pankuweit; B Maisch
Journal:  Med Klin (Munich)       Date:  1998-04-15

Review 6.  Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases.

Authors:  Gerd Wallukat; Ingolf Schimke
Journal:  Semin Immunopathol       Date:  2014-04-29       Impact factor: 9.623

Review 7.  Recent insights into the role of autoimmunity in idiopathic dilated cardiomyopathy.

Authors:  Jason M Lappé; Clara M Pelfrey; W H Wilson Tang
Journal:  J Card Fail       Date:  2008-05-27       Impact factor: 5.712

Review 8.  [Immunoadsorption for treatment of dilated cardiomyopathy].

Authors:  S B Felix; M Dörr; L R Herda; D Beug; A Staudt
Journal:  Internist (Berl)       Date:  2008-01       Impact factor: 0.743

9.  Immunoadsorption and subsequent immunoglobulin substitution decreases myocardial gene expression of desmin in dilated cardiomyopathy.

Authors:  Angela Kallwellis-Opara; Alexander Staudt; Christiane Trimpert; Michel Noutsias; Uwe Kühl; Matthias Pauschinger; Heinz-Peter Schultheiss; Markus Grube; Michael Böhm; Gert Baumann; Uwe Völker; Heyo K Kroemer; Stephan B Felix
Journal:  J Mol Med (Berl)       Date:  2007-10-09       Impact factor: 4.599

10.  Immunoadsorption therapy for patients with dilated cardiomyopathy and heart failure.

Authors:  Uichi Ikeda; Hiroki Kasai; Atsushi Izawa; Jun Koyama; Yoshikazu Yazaki; Masafumi Takahashi; Makoto Higuchi; Chang-Sung Koh; Keiji Yamamoto
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.